RB filed a lawsuit against Indivior to reclaim its losses after suboxone cases were resolved.
Indivior is being charged with a $ 1.34 billion lawsuit by former owner Reckitt Benckiser (RB) for misleading marketing of the opioid addiction therapy Suboxone film. To this day, an indivior manager sits behind bars and the company has spent billions in resolution funds. In October, former Indivior CEO Shaun Thaxter was sentenced to six months in prison after pleading guilty to receiving Medicaid coverage for Suboxone through misleading statements.
FDA Commissioner Stephen M. Hahn, MD said at the time, “Opioid addiction and abuse is a huge public health crisis and it is one of the FDA’s top priorities to take action to address it. Providing misleading information about the relative benefits of the product could undermine efforts to provide affordable treatment for those affected by this crisis. We will continue to work with the Justice Department to investigate and hold accountable those who develop and participate in programs that harm public health. “
“The public needs to be able to trust drug manufacturers and their executives – especially when they market strong opioids,” added First Assistant Attorney Daniel P. Bubar of the Western District of Virginia. “While he was Indivior’s chief executive, Shaun Thaxter violated that trust and must be held accountable.”
Photo by Brusk Dede on Unsplash
Thaxter has been fined $ 100,000 and will give up control of an additional $ 500,000. He resigned in June, the day before he pleaded guilty. The former executive has been replaced by Mark Crossley, who has been with the company since 2017.
“In July, Indivior agreed to pay $ 600 million to federal and state authorities over the next seven years after pleading guilty to misleading the Massachusetts Medicaid program about the danger of Suboxone to children,” said the Justice Department. The charge went on, “Indivior” promoted the film version of Suboxone (Suboxone Film) to doctors, pharmacists, Medicaid administrators and others across the country as being less divertable and less abusive and safer for children, families and communities than other buprenorphine drugs although such claims were never established. Indivior touted its “Here to Help” internet and telephone program as a resource for opioid dependent patients. Instead, however, Indivior used the program in part to connect patients with doctors who were known to be prescribing Suboxone tablets, although Indivior executives knew the main reason behind the hiring was to approve generic tablet forms of the Drug delay through the Food and Drug Administration. “
Now, in late November, Reckitt Benckiser has filed his lawsuit in a UK Supreme Court to reclaim funds from Indivior that it held until 2014. The damages claimed are set to cover the $ 1.4 billion settlement signed in July 2019, the DOJ claims. Back in 2019, RB had agreed to come to an agreement with the New York Attorney General and five other states that had led legal disputes over his role in the crisis.
At the time when RB settled his case, there was no admission of wrongdoing. Indivior has described the most recent case as “without merit” and has stated that he will defend himself “vigorously”.
Indivior is being charged with the Suboxone marketing plan by former parent company RB
Opioid Manufacturer Indivior’s Chief Executive Officer pleads guilty over drug safety claims
The Department of Justice receives $ 1.4 billion from Reckitt Benckiser Group for the largest recovery in an opioid drug case in United States history